# Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

> **NCT07730177** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sanaria Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Malaria (Plasmodium Falciparum)

## Interventions

- **BIOLOGICAL:** PfSPZ-LARC2 Vaccine
- **BIOLOGICAL:** PfSPZ Challenge
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT07730177
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-03
- **Primary completion:** 2027-12
- **Final completion:** 2028-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730177, "Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*